Fusion Pharmaceuticals launches with $25 million to develop cancer treatment

Fusion Pharmaceuticals has launched with $25 million to develop a treatment for cancer.

Fusion, based in Ontario, Canada, is developing a targeted deliver of alpha particles to kill tumor cells “with remarkable precision and unprecedented potency.”

It will use the Series A financing from venture investor Johnson & Johnson Innovation, HealthCap, TPG Biotech, Genesys Capital and FACIT to advance its lead program, FPX-01, into human clinical trials.

Photo credit: the Pharma Letter

Related News

Comments are closed

Copyright 2017 IMPACT ALPHA. All RIGHTS RESERVED.